Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically ...

Deputies report that the 86-year-old man, whose name is still being withheld while his family is notified, did not return to ...

With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...

Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") announced today that Health Canada has granted approval for VANRAFIATM (atrasentan tablets) for proteinuria reduction in adults with primary ...

Chai Discovery has signed a collaboration with Novartis (NOVN: VX) to use artificial intelligence in the discovery of ...

Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function ...

The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis’s oncology capabilities.

Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a ...

The acquisition is expected to close in the second half of 2026, pending customary closing conditions and regulatory ...

Novartis stock has delivered an 87.6% return over the past five years, yet its current valuation checks point to a mixed ...

Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips.

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...